Conversely, the expression of bothITGB3 and STAT4gene products from non-malignant cell types in the tumor microenvironment has previously been shown to support anti-tumor immunity (Wolff et al. 2017; –Wu et al. 2022), and high THBS1 in blood serum of AML patients predicts better prognosis (Laverdière et al. 2016). This evidence concerns the gene THBS1 and acute myeloid leukemia.